0.025) at follow-up, most neuropsychological data and basal HP hormone levels did not change over time. HPA regulation and diurnal rhythmicity of cortisol remained intact in all patients. The 24-hour mean cortisol levels decreased 6 months after surgery (p = 0.002) correlating with improved postoperative depression (p = 0.02). Conclusions: Chronic application of high-frequency electrical stimuli in the STN was not associated with HP dysfunction in patients with advanced PD. The diurnal variability of peripheral cortisol secretion as one important element of the endogenous biological clock remained intact. Evening cortisol levels decreased after surgery reflecting a favorable regulation of the cortisol setpoint. STN-DBS can be considered safe from a neuroendocrine perspective, but the origin of unwanted side effects warrants further elucidation.
. However, STN-DBS can be associated with dysregulation of mood and behavior, for example increased apathy and suicidality, in about 10% of cases [3] [4] [5] . Many PD patients also experience a noticeable weight gain under STN-DBS, particularly during the first 6 months after surgery [6, 7] . Although the exact mechanism of DBS action is still unknown, recent evidence indicates that projection fibers are not only stimulated in the immediate target region but also in remote cortical areas. A current hypothesis assumes an overwriting of abnormal oscillating basal ganglia activity with high-frequency tonic firing by the stimulation field [8] . Because the STN exhibits close anatomical and functional connections with the limbic system [9] , this artificial monotonous brain activity might also influence the hypothalamic-pituitary (HP) system, particularly the physiological circadian variability of hormone secretion. HP dysfunction often leads to apathy, depression, weight gain and peripheral hypercortisolism, which is a common finding in depressive patients [10] [11] [12] . The loss of physiological circadian rhythms and a nonreactive HP system has been demonstrated in patients with metabolic syndrome and chronic stress ('burnout HP') [13] .
In this prospective study, we aimed to investigate whether STN-DBS is associated with dysfunction of the HP-adrenal (HPA), HP-gonadal and HP-somatotropic system as a possible cause for neuropsychiatric and autonomous side effects of the procedure. In particular, we focused on the hypothesis that DBS is associated with a disturbed diurnal variability of cortisol secretion.
Methods

Patients
Eleven patients with PD diagnosed according to the UK Brain Bank criteria [14] were included in the study (6 women, 5 men, mean age 63 8 7 years, age at disease onset 49 8 7 years, disease duration 14 8 4 years, preoperative levodopa equivalence dose (LEDD) 1,050 8 300 mg). The study was approved by the local ethical committee in accordance with the Declaration of Helsinki. All patients signed written informed consent before inclusion. Each patient fulfilled the criteria for surgical intervention due to either severe on-off fluctuations or dopaminergic dyskinesia, or both, which were refractory to medication. Exclusion criteria for study participation were metabolic disorders such as diabetes mellitus, thyroid and adrenal dysregulation or eating disorders. None of the female patients were using oral contraceptives or estrogen replacement therapy. Bilateral STN electrodes (Medtronic model 3389; Medtronic, Minneapolis, Minn., USA) and impulse generators (Kinetra; Medtronic GmbH) were implanted with microelectrode recordings, macrostimulation and intraoperative neurological assessments as reported previously [15] . After surgery, DBS parameters and PD medication were adapted individually ( table 1 ) .
Clinical, Anthropometric and Neuropsychological Assessments
All patients were scored on the Unified Parkinson's Disease Rating Scale (UPDRS) part III (motor score) in the drug-off and drug-on conditions. Anthropometric examinations included body weight, body mass index (BMI), hip and waist circumferences as well as the hip-to-waist ratio. Neuropsychological functioning was assessed in drug-on at baseline and in the DBS-on/ drug-on state at follow-up visits. Mood was evaluated using the Montgomery Asberg Rating Scale (MADRS) and the Beck Depression Inventory (BDI). The Parkinson Neuropsychometric Dementia Assessment (PANDA) and the Mattis Dementia Rating Scale (MDRS) were used to measure global cognitive function. Apathy was scored with the Apathy Evaluation Scale [16] . The psychopathological state was documented and summarized using the AMDP system (Association for Methodology and Documentation in Psychiatry).
Hormone Measurements
All study subjects had blood drawn through an intravenous line. Serum samples were quick frozen and initially kept at -20 ° C. Basal hormone sampling of the HP system included morning levels after overnight fasting of (i) the HPA axis with adrenocorticotropin (ACTH) and cortisol, (ii) the HP-somatotropic axis with growth hormone (GH) and insulin-like growth factor 1 (IGF-1), and (iii) the HP-gonadal axis with luteinizing hormone (LH), follicle-stimulating hormone (FSH), sex hormone-binding globulin (SHGB), testosterone and estradiol. Diurnal variation of the HPA axis was investigated by hourly cortisol samples from 8 a.m. until 8 a.m. the next day including documentation of the sleep-wake status. For testing of overnight HPA suppression, 2 mg dexamethasone was administered orally at 11 p.m. and serum cortisol levels were obtained at 8 a.m. the following day. A serum cortisol level below 50 n M (1.8 g/dl) was the cut-off point for normal HPA reactivity [17] . Hormone assays were conducted in the Endocrinology Laboratory of the University Hospital in Frankfurt/Main using commercially available automated assays (Immulite 2000/ ADVIA Centaur CP; Siemens Diagnostics, Germany).
Fitting of Circadian Cortisol Profiles
The individual cortisol levels obtained during the 24-hour period were fitted to a cosine function, which models hormone levels over time as a sinusoidal function [18] :
The following parameters were derived from this equation: the mesor or 24-hour mean ( ␣ ), the mean morning cortisol (1 a.m. to 8 a.m.), the mean evening cortisol (6 p.m. to 1 a.m.), the amplitude ( ␤ ) between the mean and peak cortisol levels, and finally the acrophase ( ␥ ) indicating the individual nadir and peak times relative to 8 a.m. Calculations were performed with custom-built programs written in MATLAB version 2007a (The MathWorks, Inc., Natick, Mass., USA).
Statistical Analysis
Statistics were performed with SPSS for Windows version 19.0 (SPSS, Inc., Chicago, Ill., USA). Clinical baseline and follow-up data were analyzed with paired t test statistics. For hormone values and neuropsychological data, we used a repeated-measures analysis of variance (ANOVA) and, in case of significant differences, paired t tests between the means of particular time-points. Bivariate Spearman correlation was used to determine a relationship between changes of hormone levels, anthropometric measures and neuropsychological test results. The significance threshold was set at p ! 0.05 (two-tailed).
Results
Clinical Outcome
The UPDRS III scores markedly improved 6 months after surgery (pre-OP med-off 49 8 21 vs. post-OP med-off/ DBS-on 28 8 15, p ! 0.0001, paired t test). The LEDD was significantly reduced by 47.6 8 14% (range 25-73%, p ! 0.0001, paired t test) after 6 months, but all patients continued on oral levodopa therapy. DBS stimulation parameters at 6-month follow-up were: amplitude 3.0 8 0.6 V in the right and 2.8 8 0.5 V in the left hemisphere, impulse width 65 8 12 s, frequency 130 8 0 Hz. The DBS mode was monopolar in 9 and bipolar in 2 patients. One male patient had relapsing manic episodes beginning around 4 weeks after surgery, which led to several hospitalizations. Symptoms improved under clozapine treatment and disappeared completely 6 months later. A further male patient developed persistent apathy (apathy scale at baseline 15 points, 3 months post-OP 16 points, 6 months post-OP 33 points).
Neuropsychological Testing
Global cognitive function measured with the MDRS deteriorated over time, while mood, apathy and psychopathological status did not change ( table 2 ) . Although transient and slight increases of the MARDS, AMDP and apathy scores were observed at the 3-month follow-up, these changes were not significant.
Anthropometric Measures
Patients showed weight gain from 71.5 8 15.3 kg at baseline to 76.6 8 14.6 kg (p = 0.025) 6 months after surgery and an increase of the hip-to-waist ratio and of the BMI (25.5 8 4.0 vs. 27.3 8 3.1, p = 0.023) ( table 2 ) .
HPA Axis
The basal cortisol and ACTH levels did not change over time (baseline vs. 3-month vs. 6-month data): cortisol 15.4 8 6.7 vs. 14.9 8 7.6 vs. 14.0 8 6. ( table 3 ) , holding also true for both patients with psychiatric side effects. The 24-hour mean cortisol levels were lower at the 6-month follow-up (7.3 8 3.5 g/dl) compared to baseline (9.1 8 2.6 g/dl; p = 0.05, paired t test; table 3 ), particularly during the evening hours (p = 0.001, paired t test), whereas the morning levels remained largely stable over time. The individual changes of 24-hour mean cortisol correlated positively with those of the MADRS score (r = 0.69, p = 0.02; Spearman rank correlation) after 6 months and with changes of the AMDP after 3 months (r = 0.71, p = 0.015) (data not shown). There was no significant correlation of hormone alterations with individual stimulation amplitudes and with changes of neuropsychological and anthropometric measures.
HP-Gonadal and HP-Somatotropic Axis
We did not find significant differences of the genderstratified FSH, LH, estradiol, testosterone and SHBG levels before and after surgery ( table 4 A). Moreover, the GH and IGF-1 values did not differ significantly between baseline and follow-up ( table 4 B).
Discussion
Our rationale to investigate the impact of STN stimulation on neuroendocrine functioning was the fact that STN-DBS is complicated by psychiatric side effects and an apparently altered energy homeostasis in a considerable number of patients. The coincidence of psychiatric symptoms, apathy and weight gain is frequently found in various diseases of the hypothalamus. Moreover, disturbances of the HP axis are a well-known phenomenon in psychiatric disorders, for which an abnormal processing of external stressors by the limbic system with subsequent neuroendocrine dysregulation is postulated in current pathogenetic models [19] [20] [21] .
The STN is involved in hypothalamic regulation via close anatomical and functional connections with the limbic system [9] . Therefore, STN stimulation could act as an internal stressor of the limbic system. At the current state of knowledge, DBS represents a 'noise source' considered to disrupt abnormal bursting activity in the parkinsonian basal ganglia [22] . The tonic overdriving of pathological beta oscillations has been shown to reduce bursting activity and spike variability leading to regularization of neuronal firing patterns across the basal gan- glia circuits [8] . Recent neuroimaging studies demonstrated that STN-DBS drives STN output not only in the immediate target region, but also in remote and widespread areas of the basal ganglia, brainstem, cerebellum and cortex [23] . Thus, STN-DBS is believed to excite not only axons originating from the target nucleus itself, but also fiber tracts passing through the STN area and cortical afferents to the STN [24, 25] . Among these are reciprocal connections with the ventral pallidum, which is the major output region of the limbic basal ganglia circuit [26, 27] . The medial forebrain bundle running in direct vicinity of the STN gets tributaries from it and connects the ventral tegmental area of the midbrain, the lateral hypothalamus, ventral striatum, nucleus accumbens and the septal area [28] . Recently, magnetic resonance fiber tracking in a single PD patient with STN-DBS showed that acute DBS-induced hypomania occurred when the electrode contact in direct vicinity of the STN tributaries to the left medial forebrain bundle was stimulated [29] . In addition, ascending serotoninergic fibers from the midbrain raphe nuclei, which also cross the subthalamic area, have been shown to modulate endogenous clock neurons in the hypothalamic suprachiasmatic nucleus [30] .
The basal HP hormone levels and the diurnal cortisol secretion profiles did not change over time in our study cohort. Although 2 patients developed relevant psychiatric side effects, the individual hormone profiles of both were without abnormal findings. Moreover, regular dexamethasone suppression in each study participant excluded a non-reactive 'burnout' HPA system, which is characteristic for obesity related to chronic stress [13] .
Our data suggest that tonic overwriting of abnormal neuronal firing in the basal ganglia by DBS does not abrogate single-cell circadian oscillators, which generate coordinated circadian outputs and regulate physiological rhythms in the suprachiasmatic nucleus of the anterior hypothalamus [31, 32] . This particular nucleus acts as the master circadian pacemaker controlling energy homeostasis of the body by its output to parasympathetic and sympathetic centers [33] . Furthermore, endocrine glands like the adrenal gland appear to have endogenous rhythmic activity as 'peripheral clock' via the autonomic nervous system playing a major role within the physiological adrenal cortisol release [31] . Circadian rhythms have a major impact on several aspects of the mammalian physiology and behavior, in particular sleep-wake cycles, cardiovascular and endocrine activity or hepatic metabolism [34] . A number of psychiatric and sleep disorders are clearly associated with dysfunction of the central biological clock [35] . In conclusion, our data showed that highfrequency electrical stimulation close to the hypothalamus did not interact with the endogenous biological clock of the HPA axis even in PD patients suffering from psychiatric symptoms.
Our PD study group revealed lower 24-hour cortisol levels compared to baseline with a pronounced reduction in the evening hours leading to hormone levels within the range of normal volunteers [36] . Although we cannot fully prove or exclude that this phenomenon is a direct DBS effect, we propose that it rather reflects postoperative adaptation with stress reduction presumably due to improved mobility and quality of life. Thereby, the setpoint of glucocorticoid regulation seems to normalize at the level of central glucocorticoid receptor function. In favor of this hypothesis, the changes of 24-hour cortisol were significantly correlated with depression reduction on the MADRS. Glucocorticoids are important peripheral effectors of the HPA for the regulation of body homeostasis and the so-called stress response. Under stress, higher amplitudes of corticotropin-releasing hormone (CRH) pulsations lead to HPA activation with increased peripheral ACTH and cortisol secretion [37] . Since CRH is the key regulator of behavioral, neuroendocrine and autonomous adaptation under stressful conditions, a chronic hyperactivation of CRH secretion is associated with a chronic stress syndrome constituted by depression, dysphoric hyperarousal, central obesity and relative immunosuppression [38, 39] . The diurnal variation of cortisol secretion is among other factors perturbed by acute stress. The straining situation of severely disabled PD patients qualifying for DBS and the fear of the pending operation is very likely a potent stressor causing high peripheral cortisol levels during the baseline diagnostic work-up. These stressful conditions were clearly relieved 6 months later after most patients had successfully adapted to chronic STN stimulation. In line with this hypothesis, we observed lower postoperative ACTH levels compared to baseline, but this difference did not reach significance. The postoperative reduction of dopaminergic medication could also have some impact on peripheral cortisol levels. However, previous findings that high doses of levodopa lower cortisol in patients with advanced PD argue against this assumption [40] . The data of this pilot study suggest that STN-DBS can be considered widely safe from the perspective of the neuroendocrinologist. Nevertheless, 2 patients of our small study cohort experienced relevant psychiatric side effects and a significant increase of body weight and BMI was also observed over the entire group which is in line with previous reports [7, 41] . Moreover, global cognitive functioning measured with the MDRS deteriorated in our DBS cohort. Therefore, a thorough search for alternative pathophysiological explanations for these phenomena is needed. Despite the apparently intact HP system, the non-selective nature of the artificially inserted electrical field interfering with limbic and associative circuits is the most likely reason for these unwanted side effects. A recent study in a rat PD model demonstrated that STN-DBS inhibits serotonin (5-HT) neurons in the midbrain dorsal raphe nucleus [42] . Another animal study showed a decrease of neuronal firing in raphe neurons in parallel with a lower extracellular 5-HT level in both striata and in the medial prefrontal cortex during acute STN-DBS in rats [43] . These data support the hypothesis that mood and behavior changes after STN-DBS could be primarily related to 5-HT-dependent mechanisms [44] . Another study demonstrated increased neuropeptide Y and leptin levels along with an increased BMI in PD patients with STN-DBS [45] . These authors favored a disruption of the central melanocortin system and a disturbed action of leptin as a satiety signal due to DBS current spread to the hypothalamus resulting in decreased food intake and increased energy expenditure. Further studies are needed to validate these interesting hypotheses in a larger number of PD patients with STN stimulation in vivo.
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